miRNA Regulation of T Cells in Islet Autoimmunity and Type 1 Diabetes

Martin G. Scherm¹,² · Carolin Daniel¹,²,³

Published online: 28 July 2020
© The Author(s) 2020

Abstract
Purpose of Review Regulatory T cells (Tregs) are critical contributors to immune homeostasis and their dysregulation can lead to the loss of immune tolerance and autoimmune diseases like type 1 diabetes (T1D). Recent studies have highlighted microRNAs (miRNAs) as important regulators of the immune system, by fine-tuning relevant genes in various immune cell types. In this review article, we discuss recent insights into miRNA regulation of immune tolerance and activation. Specifically, we discuss how the dysregulation of miRNAs in T cells contributes to their aberrant function and the onset of islet autoimmunity, as well as their potential as targets of novel intervention strategies to interfere with autoimmune activation.

Recent Findings Several studies have shown that the dysregulation of individual miRNAs in T cells can contribute to impaired immune tolerance, contributing to onset and progression of islet autoimmunity. Importantly, the targeting of these miRNAs, including miR-92a, miR-142-3p and miR-181a, resulted in relevant effects on downstream pathways, improved Treg function and reduced islet autoimmunity in murine models.

Summary miRNAs are critical regulators of immune homeostasis and the dysregulation of individual miRNAs in T cells contributes to aberrant T cell function and autoimmunity. The specific targeting of individual miRNAs could improve Treg homeostasis and therefore limit overshooting T cell activation and islet autoimmunity.

Keywords Immune regulation · Islet autoimmunity · Type 1 diabetes · Regulatory T cell · miRNA · Biomarker

Introduction
Type 1 diabetes (T1D) is an organ-specific autoimmune disease. Its high prevalence early in life and increasing incidence worldwide make it a considerable burden for the healthcare systems. The disease is characterized by the T cell-mediated destruction of the insulin producing beta cells in the pancreas, leading to impaired insulin secretion, hyperglycemia, and increased risk of both acute and chronic complications associated with significant morbidity and mortality [1]. FOXP3⁺ regulatory T cells (Tregs) are key players for the maintenance of immune homeostasis. Impaired Treg induction, stability and function are critically involved in the loss of immune tolerance and the activation of autoimmunity [2]. microRNAs (miRNAs) have been recently shown to contribute to immune function and homeostasis by controlling gene expression in various immune cell types, including Tregs. Targeting of miRNAs represents a promising approach to interfere with overshooting immune activation. In this review, we discuss the role of T cells for the onset and progression of islet autoimmunity and the complex interplay with miRNA regulatory networks. Furthermore, we address the therapeutic potential of miRNA targeting for future immunomodulatory strategies with the vision to interfere with autoimmunity.
miRNA Basics and Biogenesis

Small non-coding RNAs (ncRNAs) have emerged as important contributors to the regulation of various biological processes including immune regulation, function and homeostasis. They are defined by their Argonaute (AGO) family protein-mediated mode of action and their length of 20–30 nucleotides. There are three distinct families of small ncRNAs with regulatory function: miRNA (microRNA), siRNA (small interfering RNA) and piRNA (PIWI-interacting RNA). The miRNA class is the most abundant in most tissues. miRNAs are ~22 nucleotides long, single-stranded and transcribed from the genome, alone or in polycistronic clusters. They control gene expression by complementary binding of their target mRNA, recruiting AGO family proteins and inducing mRNA cleavage, translational repression or mRNA deadenylation.

The biogenesis of miRNAs is a complex multi-stage process that requires precise control and constant adjustments as required. This delicate balance between immune activation and immune tolerance is a complex and tightly regulated process that requires precise control of lymphocyte development and function, with constant adjustments as required. The importance of proper immune regulation becomes evident when these control mechanisms are dysregulated, which leads to the development and activation of autoreactive lymphocytes and thereby is a critical contributor to autoimmunity. There are more than 80 diseases with an autoimmune etiology, which can be classified into systemic or organ-specific diseases, such as Multiple Sclerosis, Rheumatoid Arthritis and T1D, which is the most common autoimmune disease in young children [21]. The disease is characterized by impaired immune tolerance mechanisms, resulting in the immune-mediated destruction of pancreatic beta cells, diabetes symptoms and complications [22]. T1D progresses through distinct identifiable stages prior to the onset of the clinically overt disease [23, 24]. The appearance of autoantibodies against islet autoantigens defines the pre-symptomatic phase of T1D, which is therefore termed islet autoimmunity. During the last decades, several

The clear discrimination between self and non-self is a critical requirement for the proper functioning of the immune system, which is detecting and eliminating harmful pathogens and distinguishing them from the organism’s own tissues. This delicate balance between immune activation and immune tolerance is a complex and tightly regulated process that requires precise control of lymphocyte development and function, with constant adjustments as required. The importance of proper immune regulation becomes evident when these control mechanisms are dysregulated, which leads to the development and activation of autoreactive lymphocytes and thereby is a critical contributor to autoimmunity. There are more than 80 diseases with an autoimmune etiology, which can be classified into systemic or organ-specific diseases, such as Multiple Sclerosis, Rheumatoid Arthritis and T1D, which is the most common autoimmune disease in young children [21]. The disease is characterized by impaired immune tolerance mechanisms, resulting in the immune-mediated destruction of pancreatic beta cells, diabetes symptoms and complications [22].

T1D progresses through distinct identifiable stages prior to the onset of the clinically overt disease [23, 24]. The appearance of autoantibodies against islet autoantigens defines the pre-symptomatic phase of T1D, which is therefore termed islet autoimmunity. During the last decades, several
autoantigens have been identified, including insulin [25], glutamic acid decarboxylase (GAD) [26], insulinoma-antigen 2 (IA2) [27, 28] and zinc transporter 8 (ZNT8) [29]. Importantly, autoantibodies can be present in the blood many years before the onset of hyperglycemia [24, 30]. Despite ongoing research efforts and although recent studies significantly contributed to our understanding of T1D pathogenesis, the molecular mechanisms underlying the heterogeneity, the onset of islet autoimmunity and the progression to symptomatic diabetes remain poorly understood.

miRNAs as Biomarkers in T1D

Biomarkers provide an objectively quantifiable manner to characterize a disease. This enables both diagnosis and treatment as early and precisely as possible, and facilitates highly targeted and personalized interventions aimed at the maximum benefit for the patient. Consequently, the interest in biomarkers for studying diseases and developing novel treatment strategies continues to grow in many areas of clinical practice.

Levels of circulating miRNAs can be analyzed in small volumes of peripheral blood. Given this minimal invasiveness and the importance of miRNAs for immune homeostasis, several studies have investigated the impact of circulating miRNAs on disease development and their suitability to predict diseases progression [52–55]. miRNAs involved in the function of lymphocytes and beta cells were found to be differentially expressed in whole blood and serum obtained from newly diagnosed T1D patients compared to healthy controls. The abundance of miR-21a and miR-93, which are involved in NF-κB signaling and negatively regulate apoptotic and inflammatory genes, was significantly reduced in peripheral blood mononuclear cells (PBMCs) of T1D patients [53]. In contrast, residual beta cell function and glycemic control in individuals with recent onset of T1D were associated with high levels of miR-25 [52], miR-146a was significantly down-regulated in PBMCs of patients with newly diagnosed T1D and the decreased miRNA expression was associated with high GAD autoantibody titers in the serum [56], while an upregulation of miR-326 correlated with the presence of autoantibodies against GAD and IA2 [54]. A meta-analysis of studies investigating circulating miRNA profiles in T1D patients revealed eleven differentially expressed miRNAs: miR-21-5p, miR-24-3p, miR-100-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275. These miRNAs are involved in immune regulation, cell proliferation and insulin processing, making them potential biomarkers for T1D [57].

Despite the importance of the pre-symptomatic phase of T1D only limited studies have investigated miRNA levels in individuals with islet autoimmunity before the onset of clinical T1D. One of these rare studies found similar miRNA levels in the serum of high-risk individuals positive for multiple islet autoantibodies and healthy controls and no specific miRNA signature could be identified in the high-risk group. Interestingly, several miRNAs were associated with glucose homeostasis and autoantibody titers and these miRNAs correlated with glycemic status and ongoing islet autoimmunity in high-risk individuals [58]. Another study investigated miRNAs in the serum of 150 autoantibody-positive and 150 autoantibody-negative family-matched siblings and found several miRNAs in the serum reflecting islet autoimmunity and progression to T1D with miR-21-3p, miR-29a-3p and miR-424-5p showing the strongest correlation [55]. Despite
these important insights, the full potential of circulating miRNAs for the assessment of T1D pathogenesis and progression is still limited due to: (1) In organ-specific diseases like T1D, profiles from whole blood or serum might not reflect the relevant changes in the affected organ or cell type. (2) Relevant changes in miRNA profiles might result from changes in the miRNA profile or the abundance of specific immune cell populations, rather than global changes in the miRNA expression. (3) Changes in miRNA abundance might result from the loss of glucose homeostasis and therefore not be related to disease pathogenesis. To overcome these limitations and to increase the explanatory power of circulating miRNAs identified in the abovementioned studies, the analysis of specific miRNAs in cell types which are directly involved in the activation and progression of autoimmunity gets into the focus.

miRNA Regulation of Regulatory T Cells

In line with their regulatory role in various biological settings, including the immune system, miRNAs have also been highlighted as direct modulators of Tregs. The Treg-specific interference with the miRNA processing machinery in mice had no effect on thymic development of Tregs, but it resulted in reduced suppressive function of Tregs and deleterious systemic autoimmunity [59••, 60••, 61, 62]. Based on these findings, multiple studies investigated the underlying mechanisms of these defects and specifically the contribution of individual miRNAs. These studies revealed miRNA regulation of thymic Treg development, Treg induction, FOXP3 expression, Treg stability and suppressive function (Table 1).

The expression of miR-10a is restricted to Tregs following the exposure to retinoic acid and the abundance of this miRNA correlates with a low susceptibility to autoimmune diseases in mice [85, 86]. miR-10a stabilizes the Treg-specific gene signature by targeting several effector T cell genes including Bcl6 and Ncor2. However, the functional targets of miR-10a may be targeted by other miRNAs as well, because miR-10a deficiency alone does not result in impaired Treg function or autoimmunity. The analysis of miRNA expression in Tregs revealed several differentially expressed miRNAs with both up- and downregulation compared to CD4<sup>+</sup>CD25<sup>+</sup> T cells. Interestingly, miR-31 which was downregulated in Tregs, directly targets the 3'UTR of Foxp3 mRNA [68]. This predicted binding was experimentally confirmed using lentiviral transduction of T cells, which resulted in reduced FOXP3 levels. In addition, miR-21, which was highly expressed in Tregs, is a positive, though indirect, regulator of FOXP3 expression. miR-155 is highly abundant in Tregs and directly regulated by FOXP3. In mouse models miR-155 deficiency resulted in impaired Treg development and homeostasis and consequently reduced levels of Tregs in the thymus and the spleen [87, 88]. In miR-155-deficient Tregs the expression of FOXP3 is reduced and instable while in vitro Treg induction is unaffected. miR-155 targets suppressor of cytokine signaling 1 (SOCS1), a negative regulator of STAT5 signaling which determines the responsiveness to IL-2, a critical regulator of Treg homeostasis [89]. However, miR-155-deficient Tregs can prevent autoimmune diseases in mice, indicating that miR-155 is crucial for FOXP3 expression and Treg stability but does not directly affect their suppressive function [87].

The efficient in vitro Treg induction is also subject to regulation by miRNAs. In vitro Treg induction experiments using both Dicer and Drosha deficient naive CD4<sup>+</sup> T cells resulted in a significantly reduced expression of FOXP3 in induced Tregs compared to wild type naive CD4<sup>+</sup> T cells [59••, 60••]. Interestingly, miRNAs with both positive and negative regulatory effects on in vitro Treg induction have been identified in a miRNA screen [90] and several miRNAs form networks to cooperatively regulate Treg induction. For example, miR-150 induced reduction of mTOR occurs only in presence of miR-99a and a similar cooperation has been shown for miR-15a-16 and 15b-16. Another miRNA targeting the PI3K/Akt/mTOR pathway is miR-126. It targets p85β, which is a regulatory subunit of PI3K, reducing PI3K/Akt/mTOR pathway activity and favoring Treg induction. By contrast, miR-126 inhibition increases the activity of the PI3K/Akt/mTOR pathway, inhibiting FOXP3 expression and impairing Treg induction [75]. miR-155 also contributes to proper Treg induction in vitro by targeting Socs1 which is in line with its role for thymic Treg generation [91]. As mentioned above, the miRNA screen also revealed miRNAs with a negative effect on Treg induction in vitro [90]. Two members of the miR-17 ~ 92 cluster, miR-17 and miR-19, negatively regulate Treg induction while they have no impact on thymic Treg development [92]. miR-17 has been shown to directly target the cAMP-responsive element binding protein 1 (Creb1) and the TGFβ-receptor II, both involved in proper Treg induction. The TGFβ signaling pathway is also a target of the miR-23-miR-27-miR-24 cluster, and consequently a high abundance of this cluster impairs Treg generation [93].

Mechanistic Dissection of miRNAs in T Cells during Autoimmunity

As illustrated above, several recent studies illustrated the importance of miRNA mediated regulation for immune homeostasis by controlling the accurate function of various immune cell subsets, including Tregs. While this makes them of considerable importance for the field, the underlying, relevant pathways ultimately triggering insufficient immune tolerance and the onset of T1D autoimmunity, remain insufficiently understood. Given the importance of proper Treg function,
induction and stability, three recent studies focused on the
direct interplay between the dysregulated expression of indi-
vidual miRNAs in T cells during the onset of autoimmunity
and impaired Treg induction from naive CD4⁺ T cells.

**miR-142-3p**

The first study showed that during islet autoimmunity in-
creased miR-142-3p expression leads to impaired epigenetic
remodeling and consequently interferes with the efficient in-
duction of Tregs and Treg stability (Fig. 1). Specifically, the
upregulation of miR-142-3p during the onset of islet autoim-
munity resulted in decreased expression of its direct target, the
methylcytosine dioxygenase Tet2, which is a mediator of
DNA demethylation. By catalyzing DNA demethylation of
regulatory regions and consequently altering the accessibility
of the DNA to transcription factors, Tet enzymes are involved
in the regulation of various cellular processes. They
are involved in the differentiation of CD4⁺ T cells in humans
and mice, as well as Treg homeostasis and function by active
demethylation of the FOXP3 conserved noncoding sequence
2 (CNS2), which ensures long-term stability of FOXP3 ex-
pression in Tregs [94–97]. The miR-142-3p mediated reduced
abundance of the epigenetic modifier Tet2 was directly linked
to impaired DNA demethylation at the FOXP3 CNS2 locus
during islet autoimmunity and led to reduced frequencies of
FOXP3⁺ Tregs in the pancreas of mice with ongoing islet

---

### Table 1 miRNAs involved in Treg induction, maintenance and function

| miRNA | miRNA regulation | miRNA target | effect on Tregs | organism | target validation | miRNA effect validation | reference |
|-------|-----------------|--------------|----------------|----------|------------------|------------------------|----------|
| let7i | up              | IGF1R        | decreased Treg induction | human     | X                | X                      | [63]     |
| miR10a | down             | IFNγ         | increased Foxp3 abundance | mouse     | X                | X                      | [64]     |
| miR15a/16 | up                 | Foxp3        | decreased Foxp3 abundance | human     | X                | X                      | [65]     |
| miR15b/16 | up                | Rictor, mTor | increased Treg induction | mouse     | X                | X                      | [66]     |
| miR17 | up               | IKZF4        | decreased Treg frequencies | mouse     | X                | X                      | [67]     |
| miR19b | up                | PTEN         | decreased Treg frequencies | mouse     | X                | X                      | [67]     |
| miR21 | up                | unknown      | increased Foxp3 abundance | human     | –                | –                      | [68]     |
| miR21 | down              | STAT3        | decreased Treg frequencies | human     | X                | –                      | [69]     |
| miR24 | down              | Foxp3        | increased Foxp3 abundance | human     | X                | –                      | [70]     |
| miR25 | up                | TGFB signaling | decreased suppression | human     | X*               | –                      | [71]     |
| miR31 | down              | Foxp3        | increased Foxp3 abundance | human     | X                | –                      | [68]     |
| miR92a | up                  | KLF2 (...)   | decreased Treg induction | human/mouse | X      | X                      | [42]     |
| miR95 | up                | unknown      | increased Foxp3 abundance | human     | –                | –                      | [70]     |
| miR99a | up                 | mTor         | increased Treg induction | mouse     | X                | X                      | [72]     |
| miR100 | up               | SMAD2/3      | decreased Treg induction | human     | X                | X                      | [73]     |
| miR125a-5p | down                | CXCL13       | decreased Treg frequencies | human     | X*               | –                      | [74]     |
| miR126 | down               | p85B         | decreased Treg induction | human/mouse | X      | X                      | [75]     |
| miR142-3p | up                 | Tet2         | decreased Treg induction and stability | human/mouse | X      | X                      | [7]      |
| miR146a | down              | STAT1        | decreased suppression | human     | X*               | –                      | [76]     |
| miR146a | down              | STAT1        | decreased suppression | mouse     | X                | X                      | [77]     |
| miR146b | up                 | TRAF6        | decreased suppression | human     | X                | X                      | [78]     |
| miR150 | up                | mTor         | increased Treg induction | mouse     | X                | X                      | [72]     |
| miR181a | up                | PI3K signaling | decreased Treg induction | human/mouse | X      | X                      | [44]     |
| miR182 | up                | Foxo1        | decreased Treg frequencies | mouse     | X                | X                      | [79]     |
| miR200a | up               | unknown      | decreased Treg frequencies | human     | –                | –                      | [80]     |
| miR210 | down              | Foxp3        | increased Foxp3 abundance | human     | X                | –                      | [70]     |
| miR210 | up                | Foxp3        | decreased Treg frequencies | human     | X                | –                      | [81]     |
| miR214 | up                | PTEN         | increased Treg frequencies | mouse     | X                | X                      | [82]     |
| miR326 | up                | Ets-1        | decreased Treg frequencies | human     | –                | –                      | [83]     |
| miR663 | up                | TGFB1        | decreased Treg frequencies | human/mouse | X      | X                      | [84]     |

*shown previously
autoimmunity. The inhibition of miR-142-3p restored Tet2 levels, improved Treg induction and stability in vitro and reduce islet autoimmunity in mouse models of islet autoimmunity in vivo. As a next step, the relevance of these findings for established human T1D and their translatability was shown in humanized mouse models. Furthermore, and in line with the complex regulatory networks targeted by individual miRNAs, the study revealed multiple miR-142-3p targets with important roles in Treg development and function. Specifically, Stat5, Smad3 and Tgf receptors (Tgfbr1, Tgfbr2 and Tgfbr3) were identified as potential targets. Stat5 is a downstream target of IL-2 involved in Treg development [98]; TGFβ exhibits potent immunoregulatory properties, including the expression of FOXP3 in Tregs via phosphorylation of Smad proteins [99]. Both signaling pathways add to the identified mechanism of Tet2-mediated DNA demethylation to ensure FOXP3 expression and maintenance and consequently proper Treg function and stability. These findings suggest that miR-142-3p targets a regulatory network of genes involved in the regulation of Treg function and stability; such a broad impact helps explain how the targeting of a single miRNA has such a considerable effect on Treg homeostasis in a highly complex setting like autoimmunity. In addition, Tet2 catalyzes the demethylation of regulatory regions of various genes. This study showed the importance of Tet2-mediated demethylation of the FOXP3 CNS2 for Treg function and stability in the context of autoimmunity. However, additional regulatory regions might be controlled by Tet2 and contribute to the regulation of FOXP3. These results offer a new mechanistic model where during islet autoimmunity miRNA142-3p/Tet2-mediated impairments in Treg induction and stability contribute to the activation and progression of islet autoimmunity. Moreover, specific targeting of miR-142-3p or Tet2 might contribute to the development of novel intervention strategies, aiming at improved Treg induction and stability to interfere with the onset of islet autoimmunity.

miR-181a

In a second study, excessive T cell activation was linked to differential miRNA expression during the onset of islet autoimmunity (Fig. 1). The excessive T cell activation was found in children with recent onset of islet autoimmunity
and resulted in enhanced frequencies and proliferation of FOXP3+CD4+ T cells, which interferes with efficient Treg induction [43, 44]. Specifically, this increased T cell activation could be directly linked to higher levels of miR-181a, which reportedly alters signaling thresholds in T cells by modulating the sensitivity to antigenic stimulation [100]. The phosphatase PTEN, which is a negative regulator of T cell activation, was identified as a direct target of miR-181a and PTEN inhibition resulted in increased PI3K signaling and activation of NFAT5. NFAT5 plays an important role for T cell activation and its abundance was increased as a result of high miR-181a levels. Furthermore, elevated miR-181a levels increased the expression of the costimulatory molecule CD28 which is also involved in the activation of the PI3K pathway [101] and consequently T cell activation. In line with these findings, the inhibition of miR-181a improved Treg induction from naive CD4+ T cells, while a miR-181a mimic resembled the impaired Treg induction observed during recent onset of islet autoimmunity. These findings were confirmed in mouse models, including those of T1D [44•]. Specifically, high levels of miR-181a and NFAT5, decreased abundance PTEN and reduced Treg induction capacity from naive CD4+ T cells were found in NOD mice with islet autoimmunity. The in vivo inhibition of miR-181a in those mice reduced islet autoimmunity, decreased CD28 and NFAT5 expression and enhanced PTEN levels. Treg induction was also improved by pharmacological inhibition of NFAT5, and in Nfat5 deficient mice where increased levels of PTEN were also observed.

miR-92a

The third study provided evidence that high levels of miR-92a during the onset of islet autoimmunity mediate the induction of T follicular helper (TFH) cell precursors as well as impaired Treg induction from naive CD4+ T cells, two mechanisms that are likely involved in the onset and progression of islet autoimmunity [42•] (Fig. 1). TFH cells, which are a subset of CD4+ T cells, provide help to B cells to produce high-affinity antibodies, making them crucial contributors to humoral immunity [102–104]. This important role for antibody production suggests TFH precursors as an important effector T cell subset in autoimmunity. Both insulin-specific and polyclonal TFH precursors were increased in children with recent onset of islet autoimmunity [42•]. Analysis of differential miRNA expression in these children identified miR-92a as upregulated and there was a positive correlation between miR-92a expression and the frequencies of TFH precursor cells in the blood. In experimental in vitro TFH induction assays, the inhibition of miR-92a reduced TFH induction, while a miR-92a mimic had the opposite effect [42•]. This was in line with the identification of several negative regulators of T cell activation including Cita4, Foxo1 and Pten as targets of miR-92a. In addition, Klf2 was identified as a novel target of miR-92a and the miR-92a mediated down-regulation of Klf2 was essential for the induction of TFH precursor cells. The decreased levels of PTEN resulted in the activation of the PI3K pathway which limits efficient Treg induction. Consequently, in vitro Treg induction was impaired in the presence of a miR-92a mimic, and high miR-92a levels in children with recent onset of islet autoimmunity were accompanied by reduced frequencies of insulin-specific Tregs. Conversely, PI3K signaling promoted TFH cell induction, since the effect of a miR-92a mimic is reduced in presence of a PI3K inhibitor and increased when PTEN signaling is inhibited.

In addition to the studies described above, miR-92a and miR-181a are also involved in the pathogenesis of other autoimmune conditions, including lymphoproliferation, Th17-mediated inflammation and autoimmune neuroinflammation [67, 105, 106].

Targeting of T Cell miRNAs and Clinical Relevance

The studies described above illustrate mechanisms by which increased miRNA expression directly contributes to autoimmunity activation and progression. These findings, as well as the general importance of miRNAs for the precise regulation of the immune system, suggest that targeting miRNAs could represent an innovative intervention strategy to improve Treg induction and stability to interfere with islet autoimmunity. The relatively simple and well-known structure of miRNAs makes them attractive drug targets. This enables the efficient targeting of miRNAs using highly specific inhibitors, while mimics can be used to increase their activity, facilitating the fine-tuning of the regulation of their target genes. The complex regulatory networks of miRNAs, with each miRNA targeting a multitude of genes, hinder the direct and precise control of individual genes. However, these complex regulatory networks provide a potential explanation of the considerable effect of individual miRNAs in various settings, including their involvement in disease pathogenesis.

In autoimmunity and T1D miRNA-targeting agents were successfully used in vitro, in mouse models of autoimmune disease, and in humanized mice, resulting in upregulation of the respective miRNA targets, improvements in Treg function and reduced islet autoimmunity [7•, 42, 44•]. Furthermore, several clinical trials are currently investigating miRNA-based therapeutics for the treatment of hepatitis C virus infection, Alport syndrome, fibrosis, lymphoma, leukemia, inflammatory bowel disease, liver cancer and wound healing (summarized in: [107, 108]). To ensure both efficacy and safety of miRNA-targeting drugs, these approaches require the selective and
targeted delivery of miRNA inhibitors to the desired cell population, which remains challenging [109]. This is particularly important for the efficient treatment of organ-specific autoimmune diseases such as T1D but also for other disease settings which require a precise and local intervention in affected cell types. Several recent approaches resulted in considerable advances regarding the uptake of miRNA targeting agents by immune cells, as well as their targeted delivery. The use of oligonucleotide encapsulation techniques and nanoparticles led to improved uptake by immune cells and combinations of antibodies and nanoparticles are an important step towards the precise targeting of T cells or even T cell subsets [110, 111]. However, the design and validation of future treatment approaches will require the development of additional targeted strategies for T cell-specific targeting of miRNAs as well as optimized humanized mouse models to mimic the mechanisms underlying human autoimmune diseases in a preclinical model.

**Conclusion**

In order to better understand the molecular mechanisms promoting the onset of autoimmunity and the progression to T1D, the contribution of individual T cell subsets and how these subsets are regulated are of great importance. miRNAs are emerging as critical contributors to immune function and homeostasis, and they fine-tune the expression of relevant genes in various immune cell types, including Tregs. Therefore, recent studies focused on the contribution of individual miRNAs to aberrant T cell function in the setting of autoimmunity and described mechanisms by which miRNA levels impact autoimmune activation and progression. These insights suggest that the targeted and specific modulation of miRNA levels has the potential to reestablish Treg function and stability and in turn interfere with autoimmunity in future intervention strategies.

**Acknowledgments** C.D. holds a professorship grant from the Excellence Program for Outstanding Female Scientists from the Helmholtz Association, is supported by a Research Group at Helmholtz Zentrum München, the German Center for Diabetes Research (DZD) and through a membership in the CRC1054 of the Deutsche Forschungsgemeinschaft (B11).

**Funding Information** Open Access funding provided by Projekt DEAL.

**Compliance with Ethical Standards**

**Conflict of Interest** Martin G. Scherm and Carolin Daniel each declare no potential conflicts of interest.

**Human and Animal Rights and Informed Consent** This article does not contain any studies with human or animal subjects performed by any of the authors.

---

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464:1293–300. https://doi.org/10.1038/nature08933.
2. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133:775–87. https://doi.org/10.1016/j.cell.2008.05.009.
3. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–24. https://doi.org/10.1038/nrm3838.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97. https://doi.org/10.1016/S0092-8674(04)00045-5.
5. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian microRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105. https://doi.org/10.1101/gr.082701.108.
6. Kameswaran V, Bramswig NC, McKenna LB, Penn M, Schug J, Hand NJ, et al. Epigenetic regulation of the DLK1-MEG3 MicroRNA cluster in human type 2 diabetic islets. Cell Metab. 2014;19:135–45. https://doi.org/10.1016/j.cmet.2013.11.016.
7. Scherm MG, Serr I, Zahn AM, Schug J, Bellusci S, Manfredini R, et al. miRNA142-3p targets Tet2 and impairs Treg differentiation and stability in models of type 1 diabetes. Nat Commun. 2019. https://doi.org/10.1038/s41467-019-13587-3 During islet autoimmunity a miR-142-3p/Tet2/Foxp3 axis in murine and human CD4+ T cells leads to impaired epigenetic remodeling and consequently interferes with the efficient induction of Tregs and impaired Treg stability.
8. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23:4051–60. https://doi.org/10.1038/sj.emboj.7600385.
9. Berezikov E. Evolution of microRNA diversity and regulation in animals. Nat Rev Genet. 2011;12:846–60. https://doi.org/10.1038/nrg3079.
10. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425:415–9. https://doi.org/10.1038/nature01957.
11. Denli AM, Tops BJ, Plasterk RHA, Ketten R, Hannon GJ. Processing of primary microRNAs by the microprocessor complex. Nature. 2004;432:231–5. https://doi.org/10.1038/nature03049.
[12] Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, et al. The microprocessor complex mediates the gene expression of microRNAs. Nature. 2004;432:235–40. https://doi.org/10.1038/nature03120.

[13] Hutvagner G, McLachlan J, Pasquinelli AE, Balint É, Tuschi T, Zamore PD. A cellular function for the RNA-interference enzyme dicer in the maturation of the let-7 small temporal RNA. Science (80–). 2001;293:834–8. https://doi.org/10.1126.science.1062961.

[14] Rand TA, Petersen S, Du F, Wang X. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell. 2005;123:621–9. https://doi.org/10.1016/j.cell.2005.10.020.

[15] Kozomara A, Birgaoanu M, Griffiths-Jones S. MiRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47:D155–62. https://doi.org/10.1093/nar/gky1141.

[16] Rodríguez-Galán A, Fernández-Messina L, Sánchez-Madrid F. Control of immunoregulatory molecules by miRNAs in T cell activation. Front Immunol. 2018;9:1–10. https://doi.org/10.3389/fimmu.2018.02148.

[17] Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129:1401–14. https://doi.org/10.1016/j.cell.2007.04.040.

[18] Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482:347–55. https://doi.org/10.1038/nature10888.

[19] Im H, Kenny PJ. MicroRNAs in neuronal function and dysfunction. Trends Neurosci. 2012;35:325–34. https://doi.org/10.1016/j.tins.2012.01.004.

[20] Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs Modulate RNA library sequencing. Cell. 2007;129:1401–14. https://doi.org/10.1016/j.cell.2007.04.040.

[21] Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet. 2009;373:2027–33. https://doi.org/10.1016/S0140-6736(09)60568-7.

[22] Steffes MW, Sibley S, Jackson M, Thomas W. β-Cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26:832–6. https://doi.org/10.2337/diacare.26.3.832.

[23] Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of the JDRF, the endocrine society, and the American diabetes association. Diabetes Care. 2015;38:1964–74. https://doi.org/10.2337/db15-1419.

[24] Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes patients and healthy controls to human heat-shock protein 60 peptides AA437-660 and AA394-408. Inflam Res. 2005;54:415–9. https://doi.org/10.1007/s00011-005-1362-9.

[25] Arif S, Moore F, Marks K, Bouckenhoeg T, Dayan CM, Planas R, et al. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death. Diabetes. 2011;60:2112–9. https://doi.org/10.2337/db10-1643.

[26] Ferraro A, Socci C, Stabilini A, Valle A, Monti P, Piemonti L, et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes. 2011;60:2903–13. https://doi.org/10.2337/db11-0090.

[27] Ryba-Stanislawowska M, Werner P, Brandt A, Myśliwiec M, Myśliwiowa J. Th9 and Th22 immune response in young patients with type 1 diabetes. Immunol Res. 2016;64:730–5. https://doi.org/10.1007/s12026-015-8765-7.

[28] Ferreira RC, Simons HZ, Thompson WS, Cutler AJ, Dopico XC, Smyth DJ, et al. IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. Diabetes. 2011;60:7839–46. https://doi.org/10.2337/db11-0885.

[29] Kenecke R, Wang CJ, Kapadi T, Wardzinski L, Attridge K, Clough LE, et al. Follicular helper T cell signature in type 1 diabetes. J Clin Invest. 2015;125:292–303. https://doi.org/10.1172/JCI76238.

[30] Heninger AK, Eugster A, Kuehn D, Buettner F, Kuhn M, Lindner A, et al. A divergent population of autoantigen-responsive CD4+ T cells in infants prior to b cell autoimmunity. Sci Transl Med. 2017;9:eaa8848. https://doi.org/10.1126/scitranslmed.aat8848.

[31] Serri I, Fürst RW, Ott VB, Scherr M, Nikolaev A, Gökmen F, et al. miRNA92a targets KLf2 and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity. Proc Natl Acad Sci. 2016;113:10666-10666. https://doi.org/10.1073/pnas.1606646113.

[32] High levels of miR-92a during onset of islet autoimmunity mediate the induction of TFH precursors as well as impaired Treg induction from naive CD4+ T cells, two mechanisms that are likely involved in the onset and progression of islet autoimmunity.
systematic review and bioinformatic analysis. Endocr Connect. 2017;6:773–90. https://doi.org/10.1530/ec-17-0248.

[58] Åkerman L, Casas R, Ludvigsson J, Tavira B, Skoglund C. Serum miRNA levels are related to glucose homeostasis and islet autoantibodies in children with high risk for type 1 diabetes. PLoS One. 2018;13:e0191067. https://doi.org/10.1371/journal.pone.0191067.

[59••] Chong MMW, Rasmussen JP, Rudensky AY, Littman DR. The RNAseII enzyme Drosophila is critical in T cells for preventing lethal inflammatory disease. J Exp Med. 2008;205:2449–9. https://doi.org/10.1084/jem.20071219090508c. This study shows that miRNA-dependent regulation is critical for preventing spontaneous inflammation and autoimmunity.

[60••] Cobb B, Hertweck A, Smith J, O’Connor E, Graf D, Cook T, et al. A role for dicer in immune regulation. J Exp Med. 2006;203:2519–27. https://doi.org/10.1084/jem.20061692. This study shows that T reg cell development involves Dicer-generated miRNAs.

[61] Liston A, Rudensky AY, Lu L-F, O’Carroll D, Tarakhovsky A. Dicer-dependent microRNA pathway safeguards regulatory T cell function. J Exp Med. 2008;205:1993–2004. https://doi.org/10.1084/jem.20081062.

[62] Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT, et al. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med. 2009;208:1983–91. https://doi.org/10.1084/jem.20090707.

[63] Kimura K, Hohjoh H, Fukuoka M, Sato W, Oki S, Tomi C, et al. Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis. Nat Commun. 2018;9:17. https://doi.org/10.1038/s41467-017-02406-2.

[64] Kelada S, Sethupathy P, Okoye IS, Kistasis E, Czieso S, White SD, et al. miR-182 and miR-10a Are Key Regulators of Treg Specialisation and Stability during Schistosomes and Leishmania-associated Inflammation. PLoS Pathog. 2013. https://doi.org/10.1371/journal.ppat.1003451.

[65] Liu X, Robinson SN, Setoyama T, Tung SS, D’Abundo L, Shah MY, et al. FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells. Bone Marrow Transplant. 2014;49:793–9. https://doi.org/10.1038/bmt.2014.57.

[66] Singh Y, Garden OA, Lang F, Cobb BS. MicroRNA-15b/16 enhances the induction of regulatory T cells by regulating the expression of Rictor and mTOR. J Immunol. 2015;195:5667–77. https://doi.org/10.4049/jimmunol.1401875.

[67] Liu SQ, Jiang S, Li C, Zhang B, Li Q, Mir-17-92 cluster targets phosphatase and tensin homolog and ikaros family zinc finger 4 to promote th17-mediated inflammation. J Biol Chem. 2014;289:12446–56. https://doi.org/10.1074/jbc.M114.550723.

[68] Rouas F, Fayyad-Kazan H, El Zien N, Lewalle P, Rothé F, Simion A, et al. Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Eur J Immunol. 2009;39:1608–18. https://doi.org/10.1002/eji.200838509.

[69] Dong L, Wang X, Tan J, Li H, Qian W, Chen J, et al. Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis. J Cell Mol Med. 2014;18:2213–24. https://doi.org/10.1111/jcmm.12353.

[70] Fayyad-Kazan H, Rouas R, Fayyad-Kazan M, Badran R, El Zein N, Lewalle P, et al. MicroRNA profile of circulating CD4+ T-cell regulatory T-cells in human adults and impact of differentially expressed microRNAs on expression of two genes essential to their function. J Biol Chem. 2012;287:9910–22. https://doi.org/10.1074/jbc.M111.317354.

[71] De Santis G, Ferracin M, Biondani A, Caniatti L, Rosaria Tola M, Castellazzi M, et al. Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J Neuroimmunol.
[72] Warth SC, Hoefig KP, Hickel A, Schallenberg S, Jovanovic K, Klein L, et al. Induced miR-99a expression represses Mtor cooperatively with miR-150 to promote regulatory T-cell differentiation. EMBO J. 2015. https://doi.org/10.15252/embj.201489589.

[73] Negi V, Paul D, Das S, Bajpai P, Singh S, Mukhopadhyay A, et al. Altered expression and editing of miRNA-100 regulates iTreg differentiation. Nucleic Acids Res. 2015;43:8057–65. https://doi.org/10.1093/nar/gkv752.

[74] Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated response. Cell. 2010;142:914–29. https://doi.org/10.1016/j.cell.2010.08.012.

[75] Zhao M, Tao WL, Ping LG, Zhang P, Jie DX, Tang Q, et al. Up-regulation of Foxp3 by miR-200a expression in CD4+ T cells correlates with the expression of Th17/Treg cells and relevant cytokines in psoriasis vulgaris: a case control study. Biomed Pharmacother. 2017;93:1158–64. https://doi.org/10.1016/j.biopha.2017.06.055.

[76] Zhao M, Tao WL, Ping LG, Zhang P, Jie DX, Tang Q, et al. Up-regulation of miR-210 induces immune dysregulation via targeting FOXP3 in CD4+ T cells of psoriasis vulgaris. Clin Immunol. 2014. https://doi.org/10.1016/j.clim.2013.10.009.

[77] Paulo,0036684.

[78] Takahashi H, Kanno T, Nakayamada S, Hirahara K, Sciumè G, Jeker LT, Zhou X, Gershberg K, de Kouchkovsky D, Morar Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated response. Cell. 2010;142:914–29. https://doi.org/10.1016/j.cell.2010.08.012.

[79] Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated response. Cell. 2010;142:914–29. https://doi.org/10.1016/j.cell.2010.08.012.

[80] Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated response. Cell. 2010;142:914–29. https://doi.org/10.1016/j.cell.2010.08.012.

[81] Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated response. Cell. 2010;142:914–29. https://doi.org/10.1016/j.cell.2010.08.012.

[82] Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated response. Cell. 2010;142:914–29. https://doi.org/10.1016/j.cell.2010.08.012.

[83] Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated response. Cell. 2010;142:914–29. https://doi.org/10.1016/j.cell.2010.08.012.

[84] Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated response. Cell. 2010;142:914–29. https://doi.org/10.1016/j.cell.2010.08.012.

[85] Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated response. Cell. 2010;142:914–29. https://doi.org/10.1016/j.cell.2010.08.012.

[86] Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated response. Cell. 2010;142:914–29. https://doi.org/10.1016/j.cell.2010.08.012.

[87] Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated response. Cell. 2010;142:914–29. https://doi.org/10.1016/j.cell.2010.08.012.

[88] Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated response. Cell. 2010;142:914–29. https://doi.org/10.1016/j.cell.2010.08.012.
[102] Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med. 2000;192:1545–52.

[103] Serr I, Daniel C. Regulation of T follicular helper cells in islet autoimmunity. Front Immunol. 2018;9. https://doi.org/10.3389/fimmu.2018.01729.

[104] Scherm MG, Ott VB, Daniel C. Follicular Helper T Cells in Autoimmunity. Curr Diab Rep 2016;16. https://doi.org/10.1007/s11892-016-0770-2, 75.

[105] Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008;9:405–14. https://doi.org/10.1038/ni1575.

[106] Ghorbani S, Talebi F, Chan WF, Masoumi F, Voigani M, Power C, et al. MicroRNA-181 variants regulate T cell phenotype in the context of autoimmune neuroinflammation. Front Immunol. 2017;8. https://doi.org/10.3389/fimmu.2017.00758.

[107] Bonneau E, Neveu B, Kostantin E, Tsongalis GJ, De Guire V. How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. Electron J Int Fed Clin Chem Lab Med. 2019.

[108] Hanna J, Hossain GS, Koerber J. The potential for microRNA therapeutics and clinical research. Front Genet. 2019;10. https://doi.org/10.3389/fgene.2019.00478.

[109] Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov. 2014;13: 622–38. https://doi.org/10.1038/nrd4359.

[110] Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell. 2008;134:577–86. https://doi.org/10.1016/j.cell.2008.06.034.

[111] Peer D, Eun JP, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science (80- ). 2008;319:627–30. https://doi.org/10.1126/science.1149859.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.